EP
LCTX icon

Eudaimonia Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Eudaimonia Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$1K – 927
2021
Q1 		$1K Buy
+500
New +$1.2K ﹤0.01% 1560

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eudaimonia Partners's LCTX Position: Q2 2021 in Review

Eudaimonia Partners sold out of Lineage Cell Therapeutics (LCTX) in Q2 2021, closing a stake of 500 shares — an estimated $1K sold.

Eudaimonia Partners first reported a position in LCTX in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 115 funds tracked by Wall St. Rank hold LCTX as of Q2 2021.

  • Eudaimonia Partners reported no remaining Lineage Cell Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 500 Lineage Cell Therapeutics shares in Q2 2021, an estimated $1K.
  • Eudaimonia Partners first reported a position in Lineage Cell Therapeutics in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's Lineage Cell Therapeutics position peaked at $1K in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.